Radiation dose to patients in diagnostic nuclear medicine. Implementation of improved anatomical and biokinetic models for assessment of organ absorbed dose and effective dose.

Andersson, Martin

2017

Document Version:
Publisher’s PDF, also known as Version of record

Link to publication

Citation for published version (APA):
Internal dosimetry of radiopharmaceuticals in diagnostic nuclear medicine is based on biokinetic and anatomical models. The biokinetic model describes the uptake and retention of the radionuclide through the human body and where the nuclide decays. The anatomical models are mathematical models and are used to estimate the energy absorbed in the body from each decay. This means that the regions defining the biokinetic models also have to be defined in the mathematical anatomic models. A new biokinetic model is created and older models are modified to fit the new adult anatomic models presented by the ICRP and ICRU. New tools are developed to facilitate the use of the new voxel based anatomic models to perform revised absorbed dose and effective dose estimations. This book is the doctoral thesis of Martin Andersson and discusses the implementation of new voxel based mathematical models into diagnostic nuclear medicine. When not working with internal dosimetry Martin likes long walks by the beach and fine dining.
Radiation dose to patients in diagnostic nuclear medicine

Implementation of improved anatomical and biokinetic models for assessment of organ absorbed dose and effective dose

Martin Andersson

DOCTORAL DISSERTATION
by due permission of the Faculty of Medicine, Lund University, Sweden.
To be defended at room 2005-7, DC, SUS, Malmö, 2017-04-21, 9:15

Faculty opponent
Professor John Harrison,
Oxford Brookes University and Public Health England, Chilton, Didcot, UK
Abstract

Radiation absorbed dose estimations for patients undergoing diagnostic examinations in nuclear medicine are performed via calculations, based on models of the human body and on the radiopharmaceutical behaviour in the body. An adult mathematical model was created and the corresponding so called specific absorbed fractions (SAF) values were published by Snyder et al. (1974) which later were updated in Medical Internal Radiation Dose (MIRD) pamphlet 5 revised and pamphlet 11 (Snyder et al., 1974; 1978).

Mathematical models for a whole family of phantoms were created by Cristy and Eckerman (1987). To estimate the radiation risk to a population examined with a specific radiopharmaceutical, the effective dose is often calculated using the tissue weighting factors from ICRP Publication 60. This thesis focuses on revising absorbed dose calculations by using updated SAF values, which are based on mathematical models described by CT or MR images generated on real patients. These have later been modified to represent the reference person given in ICRP Publication 89. Together with the adoption of the new mathematical models, the updated definition of effective dose (ICRP, 2007) has been implemented.

In Paper I an internal dosimetry computer program called “Internal Dose Assessed by Computer” (IDAC2.0) is presented and in Paper IV this software is used to calculate revised organ doses and the effective doses for five clinically important PET radiopharmaceuticals. Paper II presents a graphical user interface computer program created to facilitate arbitrary Monte Carlo simulations directly on the mathematical models for specific situations where predefined SAF values have to be applied, e.g. effective dose estimations from local skin contaminations. The specific absorbed fractions and the mathematical models are defined for predetermined structures which may be more or less realistic assumptions. In Paper III, new SAF values have been generated for the urinary bladder wall at different bladder volumes, allowing absorbed dose calculations for a dynamic urinary bladder, where the SAF value is dependent on the degree of urinary bladder filling.

In order to calculate the absorbed dose, a biokinetic model is needed. A biokinetic model describes the transfer and distribution of the modelled radiopharmaceutical in different organs and tissues. Paper VI proposes a new biokinetic model for the element indium in ionic form and the absorbed doses and the effective dose are calculated for indium-111 and indium-113m ions.

In nuclear medicine, procedures can be optimised on different parameters like diagnostic information, organ absorbed doses, or effective dose. Paper V is a review on dose management for conventional nuclear medicine imaging and PET, where the importance of several relevant parameters is discussed. The goal of the review paper is to highlight the need for establishing image quality criteria in nuclear medicine to the same extent as is done in X-ray imaging. This will facilitate observer performance studies which are needed in the search for optimal imaging conditions. The main contribution towards optimisation has up to now been the recommendation to adjust the administered activity by the patients weight. The dose management in nuclear medicine imaging requires more attention and there is a need for better use of new technology for individual patient dose management and for education and training.

In conclusion, the work behind this thesis has aimed to develop and adopt more detailed and complex anatomical and biokinetic models to enable more realistic absorbed dose calculations for examinations with radiopharmaceuticals.

Key words: Diagnostic nuclear medicine, biokinetic models, internal dosimetry, absorbed dose, effective dose
Radiation dose to patients in diagnostic nuclear medicine

Implementation of improved anatomical and biokinetic models for assessment of organ absorbed dose and effective dose

Martin Andersson
A doctoral thesis at a university in Sweden takes either the form of a single, cohesive research study (monograph) or a summary of research papers (compilation thesis), which the doctoral student has written alone or together with one or several other author(s).

In the latter case the thesis consists of two parts. An introductory text puts the research work into context and summarises the main points of the papers. Then, the research publications themselves are reproduced, together with a description of the individual contributions of the authors. The research papers may either have been already published or are manuscripts at various stages (in press, submitted, or in draft).

Cover illustration front: by Martin Andersson, a mesh version of the ICRP/ICRU adult reference computational phantoms.


© Martin Andersson 2017

Lund University, Faculty of Medicine Doctoral Dissertation Series 2017:57

Department of Translational Medicine
Medical Radiation Physics Malmö
Skåne University Hospital
SE-205 02 Malmö, Sweden

ISSN 1652-8220

Printed in Sweden by Media-Tryck, Lund University
Lund 2017
"Ett bra riff kan lösa många konflikter"

Stefan Kärnström, musiker
# Content

Acknowledgements

List of figures

Abbreviations

Original papers

Other related publications by the author

Preliminary reports

Summary

Populärvetenskaplig sammanfattning

---

**Chapter 1** Introduction and aim

**Chapter 2** Biokinetic modelling

Estimation of the total number of disintegrations

Descriptive modelling

**Chapter 3** Internal dose calculations

Anatomical models

ICRP/ICRU adult reference phantoms

Specific absorbed fraction values

Absorbed dose calculations

Sources of uncertainty in internal dosimetry

Biological effects

Effective dose calculations

**Chapter 4** Summary of papers

**Chapter 5** Discussion and future outlook

**Chapter 6** Conclusions

Bibliography
Acknowledgements

My sincere appreciation and thankfulness goes to:

- **My supervisors:**
  - *Sigrid Leide Svegborn* for taken me in and helping me evolve as a grad student. You started as my teacher but ended up as my friend.
  - *Sören Mattsson* for your inspiration and sharing your vast knowledge and always being there for me. I have really learned a lot from you. I appreciate that you always see the best in people and I will always be grateful that you have shared your international contacts with me.
  - *Lennart Johansson* for your support and sharing your knowledge of expertise to me. Even if we are more than 1 000 km apart you have always just been an email away.
  - *David Minarik* for your input and contribution.

- **My co-authors:**
  - *Marie Sydoff*, my only real colleague, thanks for introducing me to the graduate program.
  - *Ünal Ören*, even if we were in different research groups you always held my back. I can’t express how glad I am that I had you as my roomie.
  - *Mauritius Hiller* for a good collaboration and for always helping me feeling welcome in the US.

- **To the research group Center for Radiation Protection Knowledge at Oak Ridge National Laboratory, especially to Rich Leggett and Keith Eckerman for always having time and sharing your vast knowledge with me.**

- **To all the past and current members of the ICRP task group 36 for your support and help and hopefully I will continue to contribute to the group.**

- **To my present and past colleagues at the Medical Radiation Physics Malmö, Lund University and Radiation Physics, Skåne University Hospital, Malmö:**

- **To all of you at the department of Medical Radiation Physics in Lund, for me it has only been 20 km and not the other way around.**

- **And finally I would like to thank Sven Richter and the Swedish Radiation Safety Authority for financing my research otherwise this could never have happened.**
List of figures

1. Decay corrected relative retention of $^{111}$In$^{3+}$ in blood plasma as a function of time after injection. The circles represent time points in the Simonsen et al. (2009) study. The red and blue lines represent fits to the measured data using two mathematical functions as presented in Paper VI.

2. Retention of $^{111}$In in the kidneys and red blood cells as functions of time after injection. The red markers represent the fraction (in %) of $^{111}$In in kidneys and red blood cells in rats (○) and dogs (✱, □) after intravenous administration of $^{111}$InCl$_3$ (McIntyre et al., 1974; Jönsson, 1991). The blue line represents the biokinetic model for ionic indium proposed in Paper VI.


4. To the left is the former standardised GI-tract model (ICRP, 1980) and to the right is the IDAC2.0 (Paper I) version of the HATM given in ICRP Publication 100.

5. A biokinetic model for indium ions where the substance is excreted through the urinary bladder contents (Paper VI).

6. The proposed biokinetic model for systemic indium presented in Paper VI.

7. To the left, the biokinetic model with transfer coefficients for $^{111}$In. To the right, the cumulated activities for all separate compartments and the time dependent curve for “Liver 2” (Nr 3) (Paper I).

8. The ICRP/ICRU adult male (left) and female (right) reference voxel phantoms. For the right pair, all object identifier numbers (OID) are shown and for the left only a few selected OIDs are shown.

9. Monoenergetic SAF values at different energies for different volumes of the urinary bladder contents as a source region to the urinary bladder wall (Paper III).

10. The internal dose computer program developed in Paper I, where the absorbed and effective doses are calculated out of predefined SAF values (Zankl et al., 2012). The program is here presented for $^{18}$F-FDG.

11. A method to enable absorbed dose calculations for relevant target regions and effective dose estimations from an arbitrary source region (Paper II).

12. The absorbed dose to the urinary bladder wall from a 300 MBq administration of $^{18}$F-fluoride calculated with different constant voiding intervals based on the data given in ICRP Publication 128 (2015) (Paper V).

13. Absorbed dose to the urinary bladder wall for 11 cases to the left and to the right is the urinary bladder volume, the activity in the contents and the dynamic SAF from 0 to 20 hours after an $^{99m}$Tc-MAG3 examination. The red line is the hypothetic activity in the bladder without any voiding (Paper III).

14. The effective dose per MBq for twelve clinically relevant and frequently used radiopharmaceuticals (Paper V).
### Abbreviations

- **A(t)**: Activity at time \( t \)
- **\( \dot{A} \)**: Total number of disintegrations
- **AUC**: Area under the curve
- **D**: Mean absorbed dose
- **E**: Effective dose
- **FDG**: Fluorodeoxyglucose, 2-deoxy-2-fluoro-D-glucose
- **FET**: Fluoroethyltyrosine
- **FLT**: Deoxyfluorothymidine
- **HAT**: Human alimentary tract
- **ICRP**: International Commission on Radiological Protection
- **IDAC**: Internal dose assessed by computer
- **IDACSTAR**: Internal dose assessed by computer★
- **LLI**: Lower large intestine
- **MAG3**: Mercaptoacetyltriglycine
- **MIRD**: Medical Internal Radiation Dose
- **MCNP**: Monte Carlo N-particle
- **OID**: Object identifier number
- **Phantoms**: Mathematical models
- **SAF**: Specific absorbed fraction
- **ULI**: Upper large intestine
- **\( w_R \)**: Radiation weighting factor
- **\( w_T \)**: Tissue weighting factor
Original papers

This thesis is based on the following six publications, which will be referred to by their Roman numerals:

I. Internal radiation dosimetry computer program, IDAC 2.0, for estimation of patient doses from radiopharmaceuticals

Martin Andersson, Lennart Johansson, David Minarik, Sören Mattsson and Sigrid Leide Svegborn.
*Radiation Protection Dosimetry*, 2012. 150(1), 119-23

II. IDACSTAR: a MCNP application to perform realistic dose estimations from internal or external contamination of radiopharmaceuticals

Ünal Ören, Mauritius Hiller and Martin Andersson.

III. Improved estimates of the radiation absorbed dose to the urinary bladder wall

Martin Andersson, David Minarik, Lennart Johansson, Sören Mattsson and Sigrid Leide Svegborn
*Physics in Medicine and Biology*, 2014. 59, 2137-2182

IV. Organ doses and effective dose for five PET radiopharmaceuticals

Martin Andersson, Lennart Johansson, David Minarik, Sören Mattsson and Sigrid Leide Svegborn.
*Radiation Protection Dosimetry*, 2016. 169(1-4), 253-258

V. Dose management in conventional nuclear medicine imaging and PET

Martin Andersson and Sören Mattsson
*Clinical and Translational Imaging*, 2016 4(1), 21-30

VI. A biokinetic model and absorbed doses for systemic indium

Martin Andersson, Sören Mattsson, Lennart Johansson and Sigrid Leide Svegborn.
*Submitted to Physics in Medicine and Biology*

Published papers have been reproduced with kind permission from Oxford University Press (*Paper I*, *II*, and *IV*), © IOP Publishing (*Paper III*), and Springer (*Paper V*). All rights reserved.
Other related publications by the author

- **Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors**

  Martin Andersson, Lennart Johansson, David Minarik, Sigrid Leide Svegborn and Sören Mattsson.
  *EJNMMI Phys*, 2014. 1:9

- **Erratum to: Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors**

  Martin Andersson.
  *EJNMMI Phys*, 2015. 2:22

- **Use of wall-less $^{18}$F-doped gelatin phantoms for improved volume delineation and quantification in PET/CT**

  Marie Sydoff, Martin Andersson, Sören Mattsson and Sigrid Leide Svegborn
  *Physics in Medicine and Biology*, 2014. 59, pp 1097-1107

- **A phantom for determination of calibration coefficients and minimum detectable activities using a dual-head gamma camera for internal contamination monitoring following radiation emergency situations**

  Ünal Ören, Martin Andersson, Christopher Rääf and Sören Mattsson
  *Radiation Protection Dosimetry* 2016. 169(1–4), 297–302

- **Technological advances in hybrid imaging and impact on dose**

  Sören Mattsson, Martin Andersson and Marcus Söderberg
  *Radiation Protection Dosimetry* 2014. 165(1–4), 410–415 (invited)

- **Rules of the thumb and practical hints for radiation protection in nuclear medicine**

  Sören Mattsson, and Martin Andersson
  In: *Radiation Protection in Nuclear Medicine*, Editors: Sören Mattsson, Christoph Hoeschen. Springer Verlag, Germany, Berlin-Heidelberg, 2013 pp 151-159
Preliminary reports

Oral presentations:


- Optimal voiding times and initial bladder after an \(^{18}\)F-FDG administration in nuclear medicine. Andersson, M., Johansson, L., Minarik, D., Mattsson, S., Leide Svegborn, S. Swerays, Uppsala 21-23 August 2013


- IDACSTAR -a standalone program to easily Monte Carlo estimate the effective dose from internal or external contamination. Andersson, M., Ören, U. National meeting on medical physics, Kolmården, 2016
EPA (USA) cancer risk models as an alternative to effective dose to estimate the radiation risk for individual patients in health care. Andersson, M., Eckerman, K., Mattsson, S. National meeting on medical physics, Kolmården, 2016

Creating Monte Carlo dose risk estimations based direct on CAD output files and validating the estimation using a 3D printer. Andersson, M., Herrnsdorf, L. National meeting on medical physics, Kolmården, 2016

Posters:


- A study of the feasibility of using slabbing to reduce tomosynthesis review time. Dustler, M., Andersson, M., Förnvik, D., Timberg, P., Tingberg, A. SPIE Medical Imaging, San Diego, CA, USA 2013 DOI:10.1117/12.206987 (also in reviewed proceedings)


- A phantom for determination of calibration coefficients and minimum detectable activities using a SPECT/CT for internal contamination monitoring following radiation emergency situations. Ören, Ü., Andersson, M., Räåf, C.L., Mattsson, S. Optimisation in X-ray and Molecular Imaging 2015, Gothenburg 2015


- IDACSTAR – a standalone program to easy create Monte Carlo voxel simulated customized dose estimations. Ünal, Ö. Hiller, M., Andersson, M. SNMMI 11-15 June 2016 San Diego, CA, USA

Summary

Radiation absorbed dose estimations for patients undergoing diagnostic examinations in nuclear medicine are performed via calculations, based on models of the human body and on the radiopharmaceutical behaviour in the body. An adult mathematical model was created and the corresponding so called specific absorbed fractions (SAF) values were published by Snyder et al. (1974) which later were updated in Medical Internal Radiation Dose (MIRD) pamphlet 5 revised and pamphlet 11 (Snyder et al., 1974; 1978). Mathematical models for a whole family of phantoms were created by Cristy and Eckerman (1987). To estimate the radiation risk to a population examined with a specific radiopharmaceutical, the effective dose is often calculated using the tissue weighting factors from ICRP Publication 60. This thesis focuses on revising absorbed dose calculations by using updated SAF values, which are based on mathematical models described by CT or MR images generated on real patients. These have later been modified to represent the reference person given in ICRP Publication 89. Together with the adoption of the new mathematical models, the updated definition of effective dose (ICRP, 2007) has been implemented.

In Paper I an internal dosimetry computer program called “Internal Dose Assessed by Computer” (IDAC2.0) is presented and in Paper IV this software is used to calculate revised organ doses and the effective doses for five clinically important PET radiopharmaceuticals. Paper II presents a graphical user interface computer program created to facilitate arbitrary Monte Carlo simulations directly on the mathematical models for specific situations where predefined SAF values have to be applied, e.g. effective dose estimations from local skin contaminations. The specific absorbed fractions and the mathematical models are defined for predetermined structures which may be more or less realistic assumptions. In Paper III, new SAF values have been generated for the urinary bladder wall at different bladder volumes, allowing absorbed dose calculations for a dynamic urinary bladder, where the SAF value is dependent on the degree of urinary bladder filling.

In order to calculate the absorbed dose, a biokinetic model is needed. A biokinetic model describes the transfer and distribution of the modelled radiopharmaceutical in different organs and tissues. Paper VI proposes a new biokinetic model for the element indium in ionic form and the absorbed doses and the effective dose are calculated for indium-111 and indium-113m ions.

In nuclear medicine, procedures can be optimised on different parameters like diagnostic information, organ absorbed doses, or effective dose. Paper V is a review on dose management for conventional nuclear medicine imaging and PET, where the importance of several relevant parameters is discussed. The goal of the review paper is to highlight the need for establishing image quality criteria in nuclear medicine to the same extent as is done in X-ray imaging. This will facilitate observer performance studies which are needed in the search for optimal imaging conditions. The main contribution towards optimisation has
up to now been the recommendation to adjust the administered activity by the patients weight. The dose management in nuclear medicine imaging requires more attention and there is a need for better use of new technology for individual patient dose management and for education and training.

In conclusion, the work behind this thesis has aimed to develop and adopt more detailed and complex anatomical and biokinetic models to enable more realistic absorbed dose calculations for examinations with radiopharmaceuticals.
**Populärvetenskaplig sammanfattning**


I denna avhandling har en ny biologisk modell skapats för grundämnet indium i jonform (In³⁺), vilken beskriver indiums fördelning i kroppen mer realistiskt än tidigare modeller. De andra arbetena handlar om att förbättra den matematiska modellen för stråldosberäkningarna. Tidigare har det matematiska fantomet varit baserat på linjära och kvadratiska ekvationer, likt godistillverkaren Bassetts® maskot Bertie. Det fantomet har nu ersatts med mer detaljerade modeller baserade på CT- och MR-bilder från verkliga personer.

Samtidigt med införandet av mer realistiska matematiska modeller har också en uppdaterad version av riskkoeficienterna för olika strålkänsliga organ använts. Man utgår fortfarande från de överlevande i Hiroshima och Nagasaki, men risken baseras nu på risken att insjukna i cancer istället för på risken att dö i cancer.

Målet med avhandlingen är att skapa mer detaljerade modeller för hur de radioaktiva ämnena omsätts i kroppen, hur de bestrålar olika organ och vilken risk detta kan innebär.
Chapter 1
Introduction and aim

Diagnostic nuclear medicine, more recently also named functional molecular imaging, deals with medical procedures performed to help diagnose a variety of diseases. The procedures are based on the use of small (or tracer) amounts of radioactive material, where a radionuclide is attached to a ligand with specific affinity to a physiological, metabolic, or receptor-specific process. Unlike other imaging systems, which show anatomy and structure in detail, nuclear medicine can provide information on parameters like e.g. tissue blood flow, metabolism, and expression of cell receptors in normal and abnormal cells. The use of a radioactive tracer is extremely sensitive and tracer concentrations down to $10^{-12}$ mol/L can be measured. The method is also non-invasive and quite easy to use. However, to be able to detect a photon from a radioactive decay in the patient, a relatively high photon energy is required, which may create a biological effect within the body. The small risk to later in life develop a radiation-induced cancer from a diagnostic radiopharmaceutical is currently estimated based on the quantity effective dose ($E$). The effective dose is one of several parameters used to justify the clinical exposure with ionising radiation to diagnose pathologies in patients. The effective dose from a radiopharmaceutical depends on where the ionisation occurs and the total number of disintegrations and where they take place within the human body. To determine the total number of disintegrations a biokinetic model is created, where the radioactive substance is followed from injection until only an insignificant amount of the tracer remains in the body.

The purpose of a biokinetic model is to estimate the spatial and temporal distribution accounting for the decays associated with an examination using radiopharmaceuticals. A biokinetic model is created by determining which parts of the body that have an increased uptake of the radiopharmaceutical. The next step is to quantify these uptakes by means of available imaging devices, single detectors, or measurements of samples (like blood, urine, and faeces) during a time period after administration of the radiopharmaceutical. These data are then the base for information about time variation of activity in various organs. If enough data is gathered a complete system describing the transport of the tracer can be created. This method to account for transfer between organs is called compartmental modelling and is constructed mathematically by defining transfer rates of the radionuclide within different parts of the body. There are several parameters that determine the total number of disintegrations in the total body or the specific organs: the administered activity, the physical half-life of the radionuclide, the residence time of the substance, and its excretion rate via different pathways. If a biokinetic model can be constructed, there is a possibility to estimate the absorbed dose contribution from each disintegration. There are biokinetic models which are created from older studies using now outdated imaging devices.
or like in the case of ionic indium only based on animal data. These biokinetic models should be subject for revision.

To be able to estimate the location of the tracer and how much energy is deposited inside the patient, the International Commission on Radiological Protection (ICRP) jointly with the International Commission on Radiation Units and Measurements (ICRU) have created models of reference persons resembling an adult male of 73 kg and a female of 60 kg. Mathematical models describing the energy deposition from a disintegration are also referred to as phantoms in this thesis. ICRP has created biokinetic models for a large number of radiopharmaceuticals (ICRP, 1979; 1987; 1998; 2008; 2015) and performed dose estimations. As of yet, the dose estimations from ICRP have been based on stylised mathematical models, which use linear and quadratic equation models of organ and tissue shapes. The mathematical models were first introduced in the Medical Internal Radiation Dose (MIRD) pamphlet 11 (Snyder et al., 1975) improved, and completed with models representing other ages by Cristy and Eckerman (1987). Furthermore, dose calculations are generally performed using a fixed urinary bladder with a constant volume, independent on physiological or biological parameters. These simplifications may not result in a fully realistic representation of the body.

During the last decades, the ICRP has published several improvements of more detailed biokinetic and anatomical models. These improvements need to be implemented into the dose estimations of radiopharmaceuticals to be able to perform more realistic dose estimations. ICRP updated the basic anatomical and physiological data for the reference person in 2002 (ICRP, 1975; 2002) and therefore new mathematical models had to be created. Reference phantoms for adults based on CT and MR images from a real adult male and female, rather than mathematical models, were published in 2009 (ICRP, 2009). These phantoms resembled the predefined anatomical values regarding height and weight and the organs and tissues were adjusted according to the specifications given in the publication of anatomical reference values (ICRP, 2002). In 2007, ICRP published a new set of tissue weighting factors for calculation of the radiation protection unit effective dose, and several new organs and tissues were assigned weighting factors (ICRP, 1990; 2008). In the new reference phantoms, all the organs and tissues needed for the revised effective dose calculations were included and the phantoms were also created to be able to adopt a new human alimentary tract (HAT) model, describing the transfer of materials within this region (ICRP, 2006).

The overall aim of this thesis is to implement the ICRP/ICRU adult voxel phantoms for diagnostic nuclear medicine, enabling improved radiation dose estimations for diagnostic procedures with radiopharmaceuticals.
The specific aims of the thesis were to:

- create a new internal dosimetry computer program, which could perform absorbed dose calculations on the new voxel phantoms and estimate the effective dose based on the tissue weighting factors in ICRP Publication 103.
- modify existing biokinetic models for a number of radiopharmaceuticals, so that the models can be used by the recently created computer program.
- create a new biokinetic model for indium ions (In\(^{3+}\)) and perform dose calculations.
- estimate the absorbed dose to the urinary bladder wall for various degree of filling rate and volume of the bladder.
- enable a method to make Monte Carlo simulations with voxel phantoms, more user friendly.
Chapter 2
Biokinetic modelling

The main objective of biokinetic modelling in nuclear medicine is to create a model, which describes the distribution of the decays of the radionuclide. Such a model does not necessarily need to be physiologically and metabolically realistic. The model can be constructed in different ways, but all models are based on actual measured radionuclide data preferentially from healthy human volunteers. Patient data are generally measured from blood or urine samples, or may be quantified with SPECT/CT or PET/CT images. The radiopharmaceuticals can be administered via different routes depending on the examination, e.g. intravenously, orally, or via inhalation. Depending on the route of administration and the chemical properties of the radiopharmaceutical, the uptake in and excretion from various organs and tissues will differ. Therefore, it is important to measure the organ/tissue radionuclide content at different time points after administration. The uptake phase is often shorter than the retention phase and it is therefore important to make frequent measurements directly after the administration. To estimate the retention in various organs and tissues, measurements should continue until only an insignificant amount of the radionuclide remains in the body, which means that the physical decay of the tracer also has to be taken into account.

![Figure 1](image)

*Figure 1.*
Decay corrected relative retention of $^{111}$In$^{3+}$ in blood plasma as a function of time after injection. The circles represent time points in the Simonsen et al. (2009) study. The red and blue lines represent fits to the measured data using two mathematical functions as presented in Paper VI.
In Figure 1, decay corrected average plasma concentration of ionic indium from 15 healthy subjects are shown (Simonsen et al., 2009). For intravenous administration, the indium concentration starts at 100% and decreases as indium begins to distribute in the human body. To estimate the total number of disintegrations or the concentration at a specific time, a biokinetic model can be constructed. There are mainly three different methods to estimate the cumulated activity: numerical integration, least squares criterion, and compartmental modelling (Koeppe, 1996; Stabin, 2008). All are briefly described below.

All organs and tissues or other relevant structures which have an increased activity concentration in relation to the normal background uptake should be included as individual parts in the creation of the biokinetic model.

![Figure 2](image)

**Figure 2.**
Retention of $^{111}$In in the kidneys and red blood cells retention as functions of time after injection. The red markers represent the fraction (in %) of $^{111}$In in kidneys and red blood cells in rats (○) and dogs (+, □) after intravenous administration of $^{111}$InCl$_3$ (McIntyre et al., 1974; Jönsson, 1991). The blue line represent the biokinetic model for ionic indium proposed in Paper VI.

The aim of the ICRP biokinetic modelling (ICRP, 1987; 1998; 2008; 2015) is to create representative models for healthy individuals. The experimental biokinetic data, are on the other hand often based on patients. However, even for a dedicated tracer the uptake in the targeted organ is just a small fraction of the injected activity (e.g. 2-5% for dedicated brain tracers) (ICRP, 2015). Thus, as only minor alterations of the uptake in other organs are expected, the overall biokinetic data is likely relevant also for healthy individuals. In some cases, there are not sufficient human data to create a biokinetic model and in these cases animal data could be used instead. However, a biokinetic model based too heavily on animal measurements is less likely to predict a realistic human model. If animal data is needed it is better to use data from mammals of the same size as humans, such as dogs and monkeys as opposed to rats and mice. Examples of an uptake and retention phase in the kidneys and red blood cells are shown in Figure 2 where data from dogs and rats are presented at different time points after injection of $^{111}$InCl (McIntyre et al., 1974; Jönsson, 1991).
Estimation of the total number of disintegrations

The cumulated activity, or total number of disintegrations, is estimated by integration of the activity as function of time in various organs or tissues. Examples of results of the most common estimation methods are presented in Figure 1. The trapezoid method is a type of numerical integration using the measured data directly. Using least squares estimation or compartmental modelling, a function is fit to the data which may then be integrated. A sum of exponential functions is often optimised by least square criteria and transfer coefficients in a compartmental model are often developed using a maximum likelihood method e.g. SAAM II (Barrett et al., 1998). Both the trapezoid method and the method based on the sum of exponential functions are calculated for each organ and tissue independently, whereas compartmental modelling accounts for transfer of activity between relevant organs and tissues.

Numerical integration

The easiest method to calculate the total number of disintegrations $\bar{A}$ is to use the trapezoidal method:

$$\bar{A} = \sum \frac{(f(t_i)+f(t_{i+1}))}{2} \Delta t_{i,i+1}$$

(2.1)

where $f(t_i)$ is the activity in the organ or tissue $i$ and $\Delta t_{i,i+1}$ is the time difference between the two measurements $i, i+1$. The trapezoid method will only be accurate with a constant linear retention. For a convex distribution it will underestimate the cumulated activity and opposite for a concave distribution. Furthermore, this method does not take remaining activity after the last measurements into account, which may cause a large underestimation of the total number of disintegrations if the radionuclide, or its radionuclide contaminants, has a long physical half-life.

Least squares criterion

The least squares criterion is based on minimising the sum of the squared distance from the estimated line to the measured points. The most common way is to assume that a sum of first order exponentials can be used to predict the model. In the example in Figure 1 a biexponential equation is used to estimate the area under the curve (AUC) and including a component for the physical decay reflects the total number of disintegrations. The biexponential equation is given by:

$$\frac{A(t)}{A(0)} = A e^{-\lambda_{BioA}t} + B e^{-\lambda_{BioB}t}$$

(2.2)

where $A(t)$ is the time dependent activity at time $t$, $\lambda_{BioA}$ and $\lambda_{BioB}$ are the retention constants and A and B are constants with the criteria that $A + B = 1$. Unlike numerical
integration using the trapezoid method, integration of the biexponential function is not limited to the last measured point. The $\lambda_{BioA}$ and $\lambda_{BioB}$ constants may be connected to biological properties such as a fast and a slow, know or unknown process. Using the sum of first order exponentials to fit data points often results in a fit which is well optimised. There is no limit on how many terms to include in the sum of exponentials but the number included should reflect the accuracy of the data the summation is based on. Usually for modelling of radiopharmaceuticals transfer, there are no meaning more than two or three terms of exponentials.

**Compartmental modelling**

Compartmental modelling is a mathematical representation of the body or an area of the body created to study physiological or pharmacological kinetic characteristics. The transfer rate constants describe the probability of a tracer to be transferred from one compartment to another per unit time. Compartmental modelling combine all measured data points into one system. As an example, the amount of indium in plasma and red blood cells (Figure 1) or plasma retention and kidney uptake (Figure 2) may thus be connected. The concept of compartmental modelling is to create a system in which all tracers are placed in interconnected compartments. The probabilities of transfer between compartments are concentration and time independent (Goris, 2011). All compartments in a model belong to a pool, which often represents an organ or a tissue. In Figure 6 the liver pool is constructed out of two compartments. The compartments are connected with first order kinetics, meaning that transfer rates are constant and that the tracer flow only depends on the trace amount in a compartment (Giussani and Uusijärvi, 2011). This means that compartmental modelling does not account for saturation, as present for e.g. thyroid uptake of iodide, or that the tracer would affect the biological process.

**Descriptive modelling**

Descriptive modelling is a form of the modelling based on least squares criteria, and is the modelling type most frequently used by the ICRP for radiopharmaceuticals. The organs are often assumed to have an instantaneous uptake and the model only describes the excretion from that organ to the urine and faeces. It assumes immediate fractional uptake $F_s$ in pool $S$ and a sum of exponentials describes excretion and uptake according to:

$$\frac{A_S(t)}{A_0} = F_s \sum_{j=n+1}^{n+m} a_j \sum_{i=1}^{n} \left\{ a_i \frac{T_i}{T_i - T_j} \left[ e^{-\frac{\ln(2)}{T_i,eff} t} - e^{-\frac{\ln(2)}{T_j,eff} t} \right] \right\}$$

(2.3)

where $A_S(t)/A_0$ is the fraction of injected activity at time $t$ in pool $S$, $a$ is the fraction of $F_s$ uptake $j$ or elimination $i$ with the corresponding biological half-time $T_i$.\n
For most descriptive models presented in ICRP Publication 53, 80, 106, and 128, a special case of equation 2.3 is assumed, where an immediate uptake in the pool $S$ is assumed:

$$\frac{A_S(t)}{A_0} = F_s \sum_{i=1}^{n} a_i e^{\left(-\frac{t}{T_{i,eff}}\right)}$$

(2.4)

Figure 3 shows a descriptive biokinetic model for ionic indium published in ICRP Publication 53 based on equation 2.4. The ICRP model of indium is created on animal studies of mice (Castronovo et al., 1971; 1973), which assumed an initial uptake of 30% in the red (active) bone marrow, 7% in the kidneys, 20% in the liver, 1% in the spleen, and the remaining activity was given to a pool resembling a general background uptake often called “remainder” or “other soft tissue”. The initial model assumed no excretion of indium, but in ICRP Publication 53 an excretion component was included based on data from mice. This excretion was not connected to any specific biological process.

![Figure 3. A descriptive biokinetic model for indium ions presented in ICRP Publication 53 (ICRP, 1987).](image)

The most common method used in ICRP Publication 128 is to connect the excretion from the compartments to a real biological process, where the substance is transferred via the kidneys to the urinary bladder before leaving the body, or is passed through the gastrointestinal tract. The measurements of the activity in urine are often performed in biokinetic studies to be able to model a realistic urinary excretion. Measurement of activity in samples of faeces are also preferable, but faeces collection is often considered impractical. The ICRP have defined standardised biokinetic models to help create more realistic compartmental models if there is a lack of data. But all models should strive to be based on real measurements if it is possible and to use ICRP standardised models when needed.

**ICRP standardised models**

When developing a compartment model, all radioactive substances need to be located within the body. Gathering data to construct a complete compartment model is not always possible and therefore ICRP has developed several standardised models (ICRP, 1980; 2006) to facilitate the development of realistic biokinetic models based on activity in samples of
various kinds, like blood, urine, or exhaled air. The ICRP has two different blood models: one for radiopharmaceuticals which have a very short physical half-life (seconds to minutes) and follow the cardiac output (Leggett and Williams, 1995) and one model for substances that remain mainly in the blood and are assumed to be distributed according to the relative blood volume of the different organs (ICRP, 2002). There are also standardised models to describe the excretion of substances from the liver to the gastrointestinal tract via the gallbladder, and for bone seeking radionuclides deposited on the surface or in the volume of the trabecular and cortical bone. The two most commonly used standardised models in diagnostic nuclear medicine are the kidney-bladder model and the gastrointestinal tract model (ICRP, 2015). The kidney-bladder model is an age-dependent model assuming that the fraction of excreted activity in the urinary bladder has been eliminated via the kidneys and then voided with an age-dependent fixed interval. The ICRP gastrointestinal tract model (Figure 4) is defined for the Reference Man given in ICRP Publication 23 and gives transfer rates (ICRP, 1979) to be applied on various radiopharmaceuticals which are either administered orally or transferred into the model from other organs.

Figure 4. To the left is the former standardised GI-tract model (ICRP, 1980) and to the right is the IDAC2.0 (Paper I) version of the HATM given in ICRP Publication 100.
When ICRP revised the reference person in ICRP Publication 89, the colon was defined in three sections (Left colon, Right colon and Recto-sigmoid colon) instead of the earlier two (Upper large intestine (ULI) and Lower large intestine (LLI)). The new human alimentary tract model presented in ICRP Publication 100 also included mouth and oesophagus together with alternatives due to different types of orally administrated diets and a sex and age dependency. In Paper I, the revised HAT model has been incorporated into the internal dosimetry program IDAC2.0 as shown in Figure 4. When revising the biokinetic model for radiopharmaceuticals published by the ICRP the HAT model should replace the former GI-tract model (ICRP, 1979).

The effective dose revision of radiopharmaceutical dosimetry has not yet been performed by the ICRP but others have performed these revisions for the most commonly used radiopharmaceuticals in diagnostic nuclear medicine (Zankl et al., 2012; Hadid et al., 2013; Andersson et al., 2014; 2015). In Paper V, five commonly used PET radiopharmaceuticals $^{18}$F-fluoride, $^{18}$F-fluoroethyltyrosine ($^{18}$F-FET), $^{18}$F-deoxyfluorothymidine ($^{18}$F-FLT), $^{18}$F-fluorocholine, and $^{11}$C-raclopride are revised from ICRP Publication 128 to be valid for the updated reference person and compared to the most frequently used PET substance $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) (Andersson, 2016). For $^{11}$C-raclopride and $^{18}$F-FET the cumulated activity in the HAT model was incorporated by mass weighting the different colon structures as:

$$\tilde{A}(r_{\text{Right colon}}, T_D) = 0.71 \ast \tilde{A}(r_{\text{ULI}}, T_D)$$  \hspace{1cm} (2.5)$$

$$\tilde{A}(r_{\text{Left colon}}, T_D) = 0.29 \ast \tilde{A}(r_{\text{ULI}}, T_D) + 0.56 \ast \tilde{A}(r_{\text{LLI}}, T_D)$$ \hspace{1cm} (2.6)$$

$$\tilde{A}(r_{\text{Rectosigmoid colon}}, T_D) = 0.44 \ast \tilde{A}(r_{\text{LLI}}, T_D)$$ \hspace{1cm} (2.7)$$

where $\tilde{A}(r_{\text{ULI}}, T_D)$ and $\tilde{A}(r_{\text{LLI}}, T_D)$ represent the cumulated activity in the source organs in the previous model, and $\tilde{A}(r_{\text{Right colon}}, T_D)$, $\tilde{A}(r_{\text{Left colon}}, T_D)$, and $\tilde{A}(r_{\text{Rectosigmoid colon}}, T_D)$ are the segmented regions of the new colon tract. The new biokinetic data for the five revised radiopharmaceuticals is presented in Table 1.
Table 1.
Total number of disintegrations per unit of administered activity $\bar{A}/A_0$ for $^{11}$C-raclopride, $^{18}$F-choline, $^{18}$F-FET, $^{18}$F-FLT, and $^{18}$F-fluoride.

<table>
<thead>
<tr>
<th>Source organ ($r_k$)</th>
<th>$^{11}$C-raclopride</th>
<th>$^{18}$F-choline</th>
<th>$^{18}$F-FET</th>
<th>$^{18}$F-FLT</th>
<th>$^{18}$F-fluoride</th>
<th>$^{18}$F-FDG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td></td>
<td>0.27</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone surface</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.4</td>
</tr>
<tr>
<td>Brain</td>
<td>0.11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.21</td>
</tr>
<tr>
<td>Colon contents</td>
<td>0.0028</td>
<td>0.00028</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gallbladder contents</td>
<td>0.0062</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart wall</td>
<td>0.0037</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.11</td>
</tr>
<tr>
<td>Kidneys</td>
<td>0.023</td>
<td>0.14</td>
<td>0.023</td>
<td>0.053</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>0.081</td>
<td>0.42</td>
<td>0.093</td>
<td>0.34</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>Lungs</td>
<td>0.0073</td>
<td>0.047</td>
<td>0.047</td>
<td>0.33</td>
<td>1.7</td>
<td>0.079</td>
</tr>
<tr>
<td>Other organs and tissues</td>
<td>0.27</td>
<td>1.6</td>
<td>2.1</td>
<td>1.7</td>
<td>0.33</td>
<td>1.7</td>
</tr>
<tr>
<td>Red bone marrow</td>
<td>0.0098</td>
<td>0.047</td>
<td>0.25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small intestine contents</td>
<td>0.023</td>
<td>0.0018</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small intestine wall</td>
<td>0.019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spleen</td>
<td></td>
<td>0.022</td>
<td>0.015</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder contents</td>
<td>0.026</td>
<td>0.10</td>
<td>0.26</td>
<td>0.15</td>
<td>0.030</td>
<td>0.26</td>
</tr>
</tbody>
</table>

In general, there is no consistency on how to estimate the activity in the urine content in the urinary bladder. The ICRP has two different methods: one for occupationally exposed persons where the urinary bladder is assumed to have a first order kinetics with a mean residence time of 2 hours, and one for patients examined with radiopharmaceuticals where the bladder has an age dependent voiding interval and is completely emptied at each void. In biokinetic studies many different voiding intervals are presented in the literature, but the most common are voiding intervals of 2 or 4 hours (Koole et al., 2009; O’Keefe et al., 2009; Lin et al., 2010; Joshi et al., 2014). Figure 5 shows a biokinetic model where the activity is excreted from the blood plasma through the kidneys before entering the urinary bladder and then leaving the body. Independent of the voiding from the urinary bladder, the urinary bladder contents are for dose calculation almost always considered as having a fixed volume with the mass of 50 g for the adult male and 40 g for adult female (ICRP, 2002). Cloutier et al. (1973) was first to present a more realistic model with a dynamic urinary bladder which was emptied when it reached 300 mL. In the biokinetic model by Thomas et al. (1992; 1999), the contents are instead estimated out of several real physical and biological parameters. The interest in including a dynamic urinary model into
compartmental modelling has been low, probably because the data needed to describe the
dynamic urinary bladder contents are patient specific and compartmental modelling for
diagnostic examinations are performed on a general population.

![Figure 5](image)

Figure 5.
A biokinetic model for indium ions where the substance is excreted through the urinary bladder contents (Paper VI).

**Systemic compartmental modelling**

In order to develop a compartment model for a systemic substance more comprehensive
work is required. The systemic model describes the distribution of a radionuclide after it
reaches the systemic circulation and its excretion from the human body, instead of assuming
an instant organ uptake of the administered activity as is done in the descriptive model
described above. The biokinetics of iodide is one of the few radiopharmaceuticals that is
described as a systemic model by the ICRP (ICRP, 1986; 2015). ICRP also produces
biokinetic models for occupational intake where the biokinetic models of the radioactive
elements often are based on systemic models (ICRP, 2015b). The radionuclides used in
diagnostic nuclear medicine have usually a much shorter physical half-life compared to
those that are of concern for occupational exposure with the consequence that the total
number of total disintegrations in the pools are different. For radionuclides with long
physical half-life the prediction of the circulating radionuclides will be more accurate using
compartmental modelling than descriptive.

In Paper VI, a systemic biokinetic model for ionic indium was proposed, which is presented
in Figure 6. Compared to the descriptive biokinetic model for ionic indium shown in
Figure 3, a systemic model is more complex. It is also a compromise between biological
realism and practical considerations such as the quantity and quality of the underlying data.
The biokinetic model proposed in Paper VI (Figure 6) is based on human blood retention and excretion data (Goodwin et al., 1971; Simonsen et al., 2009), but the model for bone marrow, liver, kidneys, and red blood cells are based on various animal studies (Smith et al., 1960; Hosain et al., 1969; Castronovo et al., 1971; 1973; Finsterer et al., 1973; Lilien et al., 1973; Beamish et al., 1974; McIntyre et al., 1974; Jeffcoat et al., 1978; Sayle et al., 1982; Jönsson, 1991; Yamauchi et al., 1992; Nakai et al., 2000). The biokinetic model for ionic indium is only valid for molecules which bind to transferrin, such as ionic indium (In\(^{3+}\)), indium arsenide (InAs), and indium chloride (InCl\(_3\)). The model is optimised mainly using the human data. The plasma retention curve is presented as a blue line in Figure 1 and the data from Simonsen et al. (2009) is represented by the dashed red line. The biological half-time of the transferrin retention was modelled to 10.5 hours, which is in good agreement with 10 hours given by Goodwin et al. (1971). The indium bound to transferrin is transferred of 20% to bone marrow, 16% to liver, and the remaining 64% to two different “other soft tissue” compartments. The blue line in Figure 2 is the proposed indium distribution in the kidneys and the red blood cells. All transfer rates between compartments are given in Table 2. The systemic biokinetic model was generated with a modified version of the compartmental program in Paper I, which uses the iterative 4th order Runge-Kutta-Merson method and is shown in Figure 7. When performing a numerical iterative integration, the integration has to account both for the fast and the slow transfer rates in the model. This means that immediately after the
injection, a short integration time step is preferable to account for the fast transfer. After a while the distribution will be dependent on the slow transfer rates and in this case it will be better to change to a longer integration step, to reduce computational time (Leggett et al., 1993).

Table 2.
Parameter values for the systemic model for indium

<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
<th>Transfer coefficient (d⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma</td>
<td>Transferrin</td>
<td>83</td>
</tr>
<tr>
<td>Plasma</td>
<td>RBC</td>
<td>0.415</td>
</tr>
<tr>
<td>RBC</td>
<td>Plasma</td>
<td>0.0554</td>
</tr>
<tr>
<td>Transferrin</td>
<td>Bone marrow 1</td>
<td>0.316</td>
</tr>
<tr>
<td>Transferrin</td>
<td>Liver 1</td>
<td>0.253</td>
</tr>
<tr>
<td>Transferrin</td>
<td>ST1</td>
<td>0.427</td>
</tr>
<tr>
<td>Transferrin</td>
<td>ST2</td>
<td>0.586</td>
</tr>
<tr>
<td>Bone marrow 1</td>
<td>Transferrin</td>
<td>1.10</td>
</tr>
<tr>
<td>Bone marrow 1</td>
<td>Bone marrow 2</td>
<td>0.475</td>
</tr>
<tr>
<td>Bone marrow 2</td>
<td>Bone marrow 1</td>
<td>0.00831</td>
</tr>
<tr>
<td>Liver 1</td>
<td>Transferrin</td>
<td>0.475</td>
</tr>
<tr>
<td>Liver 1</td>
<td>Small intestine contents</td>
<td>0.110</td>
</tr>
<tr>
<td>Liver 1</td>
<td>Liver 2</td>
<td>0.554</td>
</tr>
<tr>
<td>Liver 2</td>
<td>Liver 1</td>
<td>0.00831</td>
</tr>
<tr>
<td>Small intestine contents</td>
<td>Colon</td>
<td>6.0</td>
</tr>
<tr>
<td>ST1</td>
<td>Plasma</td>
<td>2.37</td>
</tr>
<tr>
<td>ST2</td>
<td>Plasma</td>
<td>0.00475</td>
</tr>
<tr>
<td>Plasma</td>
<td>Kidneys 1</td>
<td>1.66</td>
</tr>
<tr>
<td>Kidneys 1</td>
<td>Plasma</td>
<td>0.0166</td>
</tr>
<tr>
<td>Kidneys 1</td>
<td>Urinary bladder contents</td>
<td>0.0268</td>
</tr>
<tr>
<td>Urinary bladder contents</td>
<td>Urine</td>
<td>6.86</td>
</tr>
</tbody>
</table>

All biokinetic curves shown in Figure 1 and 2 are decay corrected and valid for all indium isotopes. For indium there are two radioisotopes which are of clinical importance: ¹¹¹In and ¹¹³mIn. To calculate the total number of disintegrations in each pool consisting of one or more compartments, the nuclide-specific physical decay constant, $-\lambda_{phys}$, is added to the iterative integration. The total number of disintegrations in compartment “Liver” is 8.17 h with 1 MBq ¹¹¹In injected based on the transfer rates given in Table 2. The distribution of ¹¹¹In in “Liver 2” (number 3 in Figure 7) and the cumulated activities are shown in Figure 7. Cumulated activities are often given per intake of Bq or MBq and therefore the total number of disintegration has the same unit as the integration unit (Leggett and Giussani, 2015; ICRP, 2015).
The model determines the spatial and temporal distribution of the decays within the created system. Biokinetic models may also be used to determine the energy deposition for all decays in order to estimate possible biological effects. In compartmental modelling, the defined pools may be arbitrary, but in order to estimate a risk they have to correspond to the organs or tissues, referred to as source regions, which defines the ICRP Reference Person from reference values given in ICRP Publication 23 or 89 (ICRP, 1975; 2002). Therefore, a pool will hereafter be called a source region, $r_s$. 

Figure 7.
To the left, the biokinetic model with transfer coefficients for $^{111}$In. To the right, the cumulated activities for all separate compartments and the time dependent curve for “Liver 2” (Nr 3) (Paper I).
Chapter 3
Internal dose calculations

Internal dosimetry calculations are motivated by the assumption that the absorbed dose in an organ is a good predictor for biological effect at least at certain dose levels and dose rates (Noßke et al., 2012).

The absorbed dose $D$ is defined in a point as (ICRU, 2011):

$$D = \frac{d\bar{E}}{dm}$$

where $d\bar{E}$ is the mean energy imparted to matter of mass $dm$ by ionising radiation. The SI unit is J kg$^{-1}$ and is most often referred to as gray (Gy). In theory, the mean energy imparted is deposited over an infinitesimal volume, but in practise the mean energy imparted is calculated over a finite volume. This volume is called the target region (or tissue), $r_T$ (Bolch et al., 2009) resulting in a calculation of the mean absorbed dose, $\bar{D}$. The most common method to calculate absorbed dose from an internally deposited radionuclide is to use the framework provided by the MIRD Committee of the Society of Nuclear Medicine in USA. The scheme was originally published in 1968 (Loevinger and Berman, 1968) with a latest revision of the MIRD formalism given in MIRD pamphlet 21 (Bolch et al., 2009). The MIRD pamphlet 21 states that the mean absorbed dose for a time-independent system is calculated as:

$$D(r_T, T_D) = \sum_{r_s} \tilde{A}(r_s, T_D) S(r_T \leftarrow r_s)$$

where $\tilde{A}(r_s, T_D)$ is the time-integrated activity, i.e. the total number of disintegrations, in source region $r_s$ from the time of administration to the time $T_D$. $S(r_T \leftarrow r_s)$ is the mean absorbed dose in target $r_T$ per nuclear transformations in source region $r_s$ and defined as:

$$S(r_T \leftarrow r_s) = \sum_i \Delta_i \Phi(r_T \leftarrow r_s, E_i)$$

where $\Phi(r_T \leftarrow r_s, E_i)$ is the absorbed fraction from the source region $r_s$ to the target region $r_T$ divided by the mass in kilograms of the target region $r_T$ of the $i$th component in the decay scheme and $\Delta_i = E_i Y_i$ is the energy yield where $Y_i$ is the yield and $E_i$ is the mean energy of the $i$th nuclear transition of the radionuclide in joule. There are many different databases which tabulate nuclide-specific energies and the corresponding yields but the calculations presented here are all based on the nuclear decay data presented in ICRP Publication 107 (ICRP, 2008b). The MIRD formalism is a general formalism which can be used for both diagnostic and therapeutic nuclear medicine and be applied on whole
organs, tissue subregions, voxelised structures, and individual cellular compartments. The limiting factor is that there has to be a known absorbed fraction between the source and target regions for a requested radiation type and its corresponding energy. The use in therapeutic nuclear medicine often needs more detailed and individual information about anatomy and absorbed fractions than applications in diagnostic nuclear medicine.

Anatomical models

There are many different phantoms which can be used to simulate absorbed fractions between source and target regions (Xu and Eckerman, 2009). These mathematical models can be divided into three different generations: stylised, voxelised, and non-uniform rational B-spline phantoms. In each new generation, structures and features are increasingly realistic and detailed for use in Monte Carlo simulations to generate more accurate absorbed fractions. Monte Carlo simulations are performed on the mathematical models and the absorbed doses are hence calculated for target regions defined by the phantoms.

Stylised

The first generation phantoms are stylised mathematical models described by linear and quadratic equations. The most commonly used phantom in diagnostic nuclear medicine for estimation of absorbed doses to various organs and tissues is the adult phantom by Snyder et al. (1974). This was later improved and completed with phantom for other ages by Cristy and Eckerman (1987). These phantoms have been used in the ICRP publications and in biokinetic dosimetry programs (Johansson 1985; Stabin et al., 2005; Andersson et al., 2012). The mathematical models are very schematic. For the family phantoms by Cristy and Eckerman, the source regions (phantom structures) are defined based on the Reference Man defined in ICRP Publication 23 (ICRP, 1975), which is described as a Caucasian Western European or North American person. The ICRP stresses that the Reference Man does not represent a random sample of any specified population (ICRP, 1975).

Voxel

The second generation phantoms are the voxel based mathematical models derived from high-resolution computed tomography images or magnetic resonance imaging of real humans. The human images have been voxelised and all voxels have been segmented and given an object identifier number (OID), where every OID represent a source region. There have been many voxelised phantoms created for different purposes, but they are all derived from the images of one individual person (Xu and Eckerman, 2009).
Non-uniform rational B-spline

The third generation phantoms are the non-uniform rational B-spline phantoms which are based on mathematical models that use a set of control points to define surfaces. This gives the possibility to modify or introduce anatomical differences in size or describe other characteristics as, for example, a mathematical model generated to simulate respiratory motion (Segars et al., 2010).

ICRP/ICRU adult reference phantoms

The adult male and adult female ICRP/International Commission on Radiation Units and Measurements (ICRU) computational voxel phantoms were approved by ICRP in 2007 and adopted by ICRU in 2008 as reference phantoms for dosimetric calculations (ICRP, 2009). These mathematical models were constructed by adjusting the voxel phantoms of Golem (Zankl et al., 2001) and Laura (Zankl et al., 2005) to the organ masses given in the ICRP Publication 89 (ICRP, 2002) and are shown in Figure 8. The phantoms are published in ICRP Publication 110, and also available in digital format as a big text file with 143 different OIDs. From this digital phantom file, the voxel phantoms have been incorporated into the IDACSTAR computer program (Paper III). The male reference phantom is composed of 1.95 million voxels where each voxel has an axial size of 2.137 x 2.137 mm² and a height of 8.0 mm. The female reference phantom is composed of 3.89 million voxels where each voxel has an axial size of 1.775 x 1.775 mm² and a height of 4.84 mm, meaning that the female phantom has a higher spatial resolution (better defined structures than the male phantom). Unlike the previous mathematically described models, specific-absorbed fraction (SAF) values for electrons may now also be simulated using Monte Carlo methods and have been published by Zankl et al. (2012). The SAF values presented in the study of Zankl et al. (2012) have been incorporated into the internal dosimetry program IDAC2.0 (Paper I). SAF values are published for 63 source regions and 67 target region and for 25 monoenergetic photons and electrons ranging from 10 keV to 10 MeV.
Specific absorbed fraction values

Monte Carlo simulated specific absorbed fraction values represent the fraction of energy transferred from a source region to a target region divided by the mass of the target region. Normally a uniform activity concentration within the source region is assumed for the simulations. Absorbed dose is the mean energy deposition registered within the whole target region divided by its mass. The radiation emitted as consequence of a nuclear transformation is radionuclide dependent, and in ICRP Publication 107 radiation from 1252 radionuclides are listed (ICRP, 2008b). SAF values may be presented in tables for monoenergetic photons and electrons. From these tables the SAF values for the radiation components emitted from a specific radionuclide can be derived through interpolation. In Paper III, SAF values from the radionuclides in urine bladder contents source region to the urinary bladder wall target region were simulated for different urine contents volumes (Figure 9).
Absorbed dose calculations

The mean absorbed dose as defined in equation 3.2 is calculated by summing the dose contribution from all source regions to a specific target region. The total number of transformations in the source regions with energy and yield for each radiation component together, multiplied with the corresponding SAF values are gives the absorbed dose to the target region. The calculation is often straightforward, but may be extensive in cases of many separate nuclear transitions with disintegrations in several source regions connected to many target regions. Therefore, the absorbed dose calculations will be facilitated if they are automated in a computer program. Figure 10 shows the user interface of the absorbed dose calculation program presented in Paper I. In this program the user can select a radionuclide defined in the ICRP Publication 107 and insert the cumulated activities for the estimated source regions. The computer program then calculates the absorbed dose to the target regions defined by Zankl et al. (2012) which were simulated using the ICRP/ICRU reference phantoms.
Using this program, absorbed doses were calculated for both adult males and females for the proposed model of systemic indium in Paper VI. The calculated absorbed doses per intravenously administered activity are presented in Table 3 for $^{111}$In and $^{113m}$In. The effective dose is also calculated for both isotopes and are also compared with the results of earlier biokinetic models published by ICRP.
Table 3.
Absorbed doses (mGy/MBq) and the effective dose (mSv/MBq) per administered activity for the proposed indium model in Paper VI compared with the calculated effective dose from the biokinetic indium models presented in the ICRP Publication 53 and 72 as calculated by the computer program developed in Paper I.

<table>
<thead>
<tr>
<th>Organs</th>
<th>$^{111}$In [mGy/MBq]</th>
<th>$^{113}$In [mGy/MBq]</th>
<th>$^{111}$In [mGy/MBq]</th>
<th>$^{113}$In [mGy/MBq]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenals</td>
<td>3.80E-01</td>
<td>4.81E-01</td>
<td>1.49E-02</td>
<td>1.70E-02</td>
</tr>
<tr>
<td>Brain</td>
<td>9.93E-02</td>
<td>1.15E-01</td>
<td>2.92E-03</td>
<td>3.26E-03</td>
</tr>
<tr>
<td>Breast</td>
<td>1.27E-01</td>
<td>1.60E-01</td>
<td>5.30E-03</td>
<td>6.79E-03</td>
</tr>
<tr>
<td>Endosteal Bone Surface</td>
<td>1.42E-01</td>
<td>1.74E-01</td>
<td>3.78E-03</td>
<td>4.27E-03</td>
</tr>
<tr>
<td>Extrathoracic region</td>
<td>1.09E-01</td>
<td>1.44E-01</td>
<td>6.92E-03</td>
<td>7.97E-03</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>4.54E-01</td>
<td>5.33E-01</td>
<td>1.36E-02</td>
<td>1.64E-02</td>
</tr>
<tr>
<td>Gastrointestinal tract:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>2.25E-01</td>
<td>2.35E-01</td>
<td>1.48E-02</td>
<td>1.49E-02</td>
</tr>
<tr>
<td>Small intestine</td>
<td>2.27E-01</td>
<td>2.72E-01</td>
<td>1.48E-02</td>
<td>1.64E-02</td>
</tr>
<tr>
<td>Stomach</td>
<td>2.76E-01</td>
<td>3.16E-01</td>
<td>1.54E-02</td>
<td>1.68E-02</td>
</tr>
<tr>
<td>Gonads</td>
<td>1.06E-01</td>
<td>2.04E-01</td>
<td>3.48E-03</td>
<td>6.37E-03</td>
</tr>
<tr>
<td>Heart</td>
<td>2.92E-01</td>
<td>3.39E-01</td>
<td>1.09E-02</td>
<td>1.33E-02</td>
</tr>
<tr>
<td>Kidneys</td>
<td>5.58E-01</td>
<td>6.34E-01</td>
<td>3.02E-02</td>
<td>3.39E-02</td>
</tr>
<tr>
<td>Liver</td>
<td>6.39E-01</td>
<td>7.57E-01</td>
<td>2.02E-02</td>
<td>2.46E-02</td>
</tr>
<tr>
<td>Lungs</td>
<td>2.82E-01</td>
<td>3.31E-01</td>
<td>2.32E-02</td>
<td>2.83E-02</td>
</tr>
<tr>
<td>Lymph nodes</td>
<td>3.46E-01</td>
<td>5.91E-01</td>
<td>1.13E-02</td>
<td>1.62E-02</td>
</tr>
<tr>
<td>Muscle</td>
<td>1.15E-01</td>
<td>1.43E-01</td>
<td>2.58E-03</td>
<td>3.21E-03</td>
</tr>
<tr>
<td>Oesophagus</td>
<td>2.90E-01</td>
<td>3.34E-01</td>
<td>1.69E-02</td>
<td>1.92E-02</td>
</tr>
<tr>
<td>Oral mucosa</td>
<td>1.02E-01</td>
<td>1.27E-01</td>
<td>2.25E-03</td>
<td>3.02E-03</td>
</tr>
<tr>
<td>Pancreas</td>
<td>3.55E-01</td>
<td>3.79E-01</td>
<td>1.54E-02</td>
<td>1.70E-02</td>
</tr>
<tr>
<td>Prostate/Uterus</td>
<td>1.64E-01</td>
<td>2.06E-01</td>
<td>7.81E-03</td>
<td>9.88E-03</td>
</tr>
<tr>
<td>Red (active) bone marrow</td>
<td>2.17E-01</td>
<td>2.60E-01</td>
<td>6.38E-03</td>
<td>6.88E-03</td>
</tr>
<tr>
<td>Salivary glands</td>
<td>1.10E-01</td>
<td>1.43E-01</td>
<td>7.42E-03</td>
<td>8.83E-03</td>
</tr>
<tr>
<td>Skin</td>
<td>7.85E-02</td>
<td>9.53E-02</td>
<td>2.72E-03</td>
<td>3.52E-03</td>
</tr>
<tr>
<td>Spleen</td>
<td>2.91E-01</td>
<td>3.35E-01</td>
<td>2.51E-02</td>
<td>2.80E-02</td>
</tr>
<tr>
<td>Thymus</td>
<td>2.03E-01</td>
<td>2.49E-01</td>
<td>1.07E-02</td>
<td>1.30E-02</td>
</tr>
<tr>
<td>Thyroid</td>
<td>1.63E-01</td>
<td>1.91E-01</td>
<td>8.84E-03</td>
<td>1.03E-02</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>1.44E-01</td>
<td>1.58E-01</td>
<td>2.60E-03</td>
<td>3.53E-03</td>
</tr>
</tbody>
</table>

Effective dose

| $^{111}$In | 2.53E-01 mSv/MBq | 1.27E-02 mSv/MBq |
| $^{113}$In | 2.60E-01 mSv/MBq | 6.29E-03 mSv/MBq |

Effective dose (ICRP 72)

| $^{111}$In | 2.60E-01 mSv/MBq | 6.29E-03 mSv/MBq |
| $^{113}$In | 1.80E-01 mSv/MBq | 6.23E-03 mSv/MBq |
Creating customised absorbed dose values

The SAF values from Zankl et al. (2012) were simulated for source and target regions of relevant organ and tissues. Paper II presents a method created to facilitate the calculation of customised SAF values from arbitrary source regions. The method was implemented in the computer program IDACSTAR and is presented in Figure 11. IDACSTAR was created to give a graphical user interface for the ICRP/ICRU adult reference voxel phantoms which enables a customised insertion of one of the three predefined radionuclides $^{99m}$Tc, $^{18}$F or $^{131}$I into the graphical representation of the voxel phantoms.

After the activity distribution in the phantoms is defined, the program generates input files to the Monte Carlo simulation program MCNP and also starts the simulation of the nuclear decay and energy deposition within the created geometry. When the simulation is finished in MCNP, IDACSTAR catches the result file and calculates the absorbed dose to the target regions which are defined in the ICRP Publication 103 and considered to be radiosensitive, i.e. inducing biological effects later in life. IDACSTAR also enables estimation of skin contaminations, however the spatial resolution of the mathematical model is too low to be able to perform accurate skin dose estimations. The reason is that the radiosensitive part of the skin is an epidermal depth between 50 and 100 μm (ICRP, 2010; Covens et al., 2013) and the 10 μm simulation volume thickness for the radiosensitive part of the skin (Covens et al., 2013) are very small compared to the voxel depth of 2.137 mm and 1.775 mm of the male and female reference phantoms, respectively. The voxels size is a problem for all small or complex structures. For the alimentary and respiratory tract systems meshed versions of these source regions have been created (Kim et al., 2017).
Fixed urinary bladder volume

The urinary bladder wall is considered to be a radiosensitive organ for inducing cancer later in life. The absorbed dose to the urinary bladder wall depends on which voiding interval is used. The most conservative assumption is to assume no voiding at all, meaning that all activity which is transferred to the urinary bladder also decays in the urinary bladder. The absorbed doses to the urinary bladder wall were compared between different voiding intervals in Paper V (Figure 12). The absorbed doses are presented for a $^{18}$F-fluoride examination calculated assuming various urine voiding intervals ranging from 1 to 6 hours. There is a wide variety in absorbed dose depending on voiding interval, and therefore, a consensus on a suitable voiding time when performing general dose estimations to a population would be preferable. If examinations are optimised after population-based absorbed dose calculations, the assumption of voiding interval could have a real impact on the image quality and hence have a possible effect on diagnostic outcome. Therefore, examinations should be optimised on other criteria.

**Figure 12.**
The absorbed dose to the urinary bladder wall from a 300 MBq administration of $^{18}$F-fluoride calculated with different constant voiding intervals based on the data given in ICRP Publication 128 (2015) (Paper V).

Dynamic urinary bladder volume

In Paper III, absorbed dose calculations are performed based on the SAF values presented in Figure 9 using the method to estimate the volume of a dynamic urinary bladder described by Thomas et al. (1992; 1999). The estimations were performed using the data presented in Table 1 in Paper III. For a $^{99m}$Tc-mercaptaoacetylgligycine (MAG3) examination the absorbed dose to the urinary bladder wall was calculated to 0.09 mGy/MBq for males and 0.10 mGy/MBq for females. The use of volume dependent SAF values instead of fixed SAF values will result in higher absorbed dose. The assumption behind calculating absorbed doses to the urinary bladder wall where the SAF values changes with the urine content in the bladder are to simulate spherical bladder contents and bladder wall. The contents size depends only on the urine volume and the outer wall has a fixed mass. For volumes larger
than the fixed urinary bladder the SAF values will be lower and for smaller volumes the SAF values will be higher because of self-absorption within the contents itself for a uniform distributed activity. For the parameters given in Table 1 in Paper III the volume of the urinary bladder will mostly be smaller than the fixed geometry. The results of 11 different biokinetic models were compared in Paper III and are shown in Figure 13 together with the time dependent urinary bladder volume, the activity in the urinary bladder and the interpolated dynamic SAF values for 99mTc-MAG3 for the male phantom.

![Figure 13.](image)

**Figure 13.** Absorbed dose to the urinary bladder wall for 11 cases to the left and to the right is the urinary bladder volume, the activity in the contents and the dynamic SAF from 0 to 20 hours after an 99mTc-MAG3 examination. The red line is the hypothetic activity in the bladder without any voiding (Paper III).

**Sources of uncertainty in internal dosimetry**

All data and results include uncertainties. The relevance of these uncertainties is dependent on the application of the dosimetric data. When using 177Lu peptides for radionuclide therapy, the kidneys are the limiting organs at risk. Kidney dose estimates based on patient-specific calculations have a reported uncertainty of 6 % (1 SD) (Gustafsson et al., 2015). In diagnostics, however, the calculations are based on biokinetic population models, so the question is how well they represent a specific individual. Roedler (1980) showed that using reference phantoms and population-based biokinetic models will estimate the real patient dose within a factor of 3, and within a lower factor for radionuclides with short half-life e.g. 99mTc. The general proposed uncertainty is a factor of 2 or greater (Svegborn, 1999; Zanzonico, 2000; Norrgren et al., 2003; Stabin, 2008b). Other relevant questions are how well the biokinetic models and the mathematical anatomical models represent the general populations. The mathematical anatomical models are defined for a western Caucasian population. The tissue weighting factors given in ICRP Publication 103 for radiation-induced biological effects are defined for all populations, ages, and sexes. Thus, applying these factors on individuals or subgroups is incorrect and therefore this uncertainty is irrelevant. The uncertainties in the tissue weighting factors are not within the scope of this work.
The uncertainties of biokinetic modelling of indium for an age and sex independent population are unknown. The data points used to generate the indium model in Paper VI are obtained from published papers and they were often presented as mean values without any uncertainty estimation. The model is based on data gathered from small animals, e.g. rats and mice, dogs, as well as for humans. The biokinetic model was constructed by fitting the model to the mean plasma retention curve for 15 healthy subjects. The initial indium transfers between various organs and tissues will mostly be blood dependent and the uncertainty in the presented absorbed doses will probably be within the factor of 3 or less (Roedler, 1980) for the clinically used $^{111}$In- and $^{113m}$In-ions. For long-lived indium isotopes there are still not enough data available to construct a biokinetic model. After about 100 days the erythrocytes dies and indium is recycled. The uncertainties in the long-term fitting to the model are difficult to estimate. For other elements there have been various versions of the biokinetic model to account for population-based uncertainties (Pawel et al., 2007), but there is still not enough data to perform this on indium.

Biological effects

It is well known that ionising radiation has a biological effect on the human body. There are two types of harmful effects: deterministic (tissue) effects and stochastic effects (ICRP, 2007).

Deterministic effects

A deterministic effect is often of an acute nature and caused by high doses. The deterministic effects are characterised by a threshold dose after which the effect increases in severity as the dose is further increased. Situations when the dose threshold for deterministic effects in relevant organs could be exceeded should under almost all circumstances be subject for protection actions (ICRP, 2007). This thesis is concerned with stochastic effects and the results should not be applied to estimate any deterministic effects.

Stochastic effects

Stochastic effects are caused by both high and low doses, and are effects observed as a statistically detectable increase in the incidence of cancer or heritable disease occurring a long time after exposure. To estimate the biological effect from a disintegration there are two correction factors, the radiation weighting factor, $w_R$, and the tissue weighting factor, $w_T$, applied on the mean absorbed dose. The radiation weighting factors are defined largely to reflect the relative biological effectiveness for stochastic effects of different types of radiation. In diagnostic nuclear medicine $w_R = 1$ is used for all radiation types. The
tissue weighting factor is defined to reflect the relative contribution from the organ and tissue to the total detriment for stochastic effects, which is the total harm to health experienced by an exposed group and its descendants. The tissue weighting factors published in ICRP Publication 103 given in Table 4 are sex- and age-averaged values and it is stressed that the application of these factors are restricted to the effective dose definition and not used for the assessment of individual risk.

Table 4.
Tissue weighting factors $w_T$ for 13 different organs (ICRP, 2007).

<table>
<thead>
<tr>
<th>Organ</th>
<th>$w_T$</th>
<th>Organ</th>
<th>$w_T$</th>
<th>Organ</th>
<th>$w_T$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>0.12</td>
<td>Gonads</td>
<td>0.08</td>
<td>Bone surface</td>
<td>0.01</td>
</tr>
<tr>
<td>Colon</td>
<td>0.12</td>
<td>Bladder</td>
<td>0.04</td>
<td>Brain</td>
<td>0.01</td>
</tr>
<tr>
<td>Lung</td>
<td>0.12</td>
<td>Oesophagus</td>
<td>0.04</td>
<td>Salivary glands</td>
<td>0.01</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.12</td>
<td>Liver</td>
<td>0.04</td>
<td>Skin</td>
<td>0.01</td>
</tr>
<tr>
<td>Remaining tissues*</td>
<td>0.12</td>
<td>Thyroid</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Remaining tissues: Adrenals, extrathoracic (ET) region, gallbladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, prostate (♂), small intestine, spleen, thymus, and uterus/cervix (♀).

Effective dose calculations

The effective dose is a radiation protection quantity defined by the ICRP to estimate the total harm to health experienced by an exposed group and its descendants caused by stochastic effects. The quantity was first introduced in the ICRP Publication 26 and a year later the term ‘effective dose equivalent’ and the symbol $H_e$ were assigned for this new concept. Up to now ICRP has revised the weighting factors twice and also changed the name of the quantity to effective dose ($E$) (ICRP, 1977; 1978; 1991; 2007). The unit is sievert (Sv). There is an ongoing discussion related to the need to describe the advantages and limitations of effective dose in more detail (Harrison et al., 2016).

Effective dose is calculated from the equivalent dose. The equivalent dose is the absorbed dose multiplied with the radiation weighting factors $w_R$. For beta and gamma radiation the $w_R$ is equal to 1. The effective dose is then calculated as the sum of the organs tissue weighting factors multiplied by the arithmetic mean of the sex-specific equivalent dose of for each of the corresponding organs:

$$ E = \sum_T w_T \sum_R w_RD_R(r_T,T_D)_{\text{male}} + w_RD_R(r_T,T_D)_{\text{female}} $$  \hspace{1cm} (3.4)

where $w_T$ is the tissue weighting factor for tissue $T$ and $\sum_R w_RD_R(r_T,T_D)_{\text{sex}}$ is the sex-specific equivalent dose for target region $r_T$.

In Paper IV, the effective dose was estimated for $^{18}$F-fluoride, $^{18}$F-FET, $^{18}$F-FLT, $^{18}$F-choline, and $^{11}$C-raclopride, and the results are presented in Table 5.
Table 5.
The effective dose from $^{18}$F-FDG*, $^{18}$F-fluoride, $^{18}$F-FET, $^{18}$F-FLT, $^{18}$F-choline, and $^{11}$C-raclopride and the difference in % compared to the effective dose presented in ICRP Publication 128 (Paper IV).

<table>
<thead>
<tr>
<th>Radiopharmaceutical</th>
<th>This Study [mSv/MBq]</th>
<th>Difference [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{18}$F-FDG</td>
<td>1.7E-02*</td>
<td>-11</td>
</tr>
<tr>
<td>$^{18}$F-Fluoride</td>
<td>8.9E-03</td>
<td>-48</td>
</tr>
<tr>
<td>$^{18}$F-FET</td>
<td>1.5E-02</td>
<td>-6</td>
</tr>
<tr>
<td>$^{18}$F-FLT</td>
<td>1.4E-02</td>
<td>-7</td>
</tr>
<tr>
<td>$^{18}$F-choline</td>
<td>2.0E-02</td>
<td>0</td>
</tr>
<tr>
<td>$^{11}$C-raclopride</td>
<td>4.3E-03</td>
<td>-14</td>
</tr>
</tbody>
</table>

*Andersson et al., (2015)

Paper V is a review paper on dose management and presents other previously (Andersson et al., 2014; 2015) revised effective dose calculations for twelve clinically relevant radiopharmaceuticals, all shown in Figure 14.

![Figure 14. The effective dose per MBq for twelve clinically relevant and frequently used radiopharmaceuticals (Paper V).](image-url)

*68Ga-DOTA is the arithmetic mean value for 68Ga-DOTATATE, 68Ga-DOTATOC and 68Ga-DOTANOC.
The effective dose is estimated to a Reference Person and is generated from absorbed dose calculations to the Reference Male and Reference Female. In Paper II, where customised dose calculations were performed on the Reference Individuals, simulations also included sex-specific organs e.g. ovaries. By definition, effective dose estimation may not be performed if absorbed doses are known for only one of the two Reference Individuals which defines the Reference Person. Therefore, a new quantity was defined in Paper IV and named “component dose”. There could be a use for the component dose quantity even if it is formally an incorrect use of the tissue weighting factors. The reason of introducing this new quantity is to avoid undermining the effective dose quantity by using it for estimations it is neither intended nor defined for.
Chapter 4
Summary of papers

Paper I: Internal radiation dosimetry computer program, IDAC 2.0, for estimation of patient doses from radiopharmaceuticals

Paper I describes an updated version of the internal dosimetry computer program called “Internal dose assessment by computer” (IDAC), which was created to facilitate effective dose and absorbed dose calculations for organs and tissues for use in diagnostic nuclear medicine. The new version, IDAC2.0, incorporates the ICRP/ICRU adult reference voxel phantoms and decay data from ICRP Publication 107. Performing dose calculations on the SAF values based on the voxel phantoms allows biokinetic modelling of the ICRP human alimentary tract model and effective dose calculations based on the updated tissue weighting factors given in ICRP Publication 103. The introduction of the HAT model in the program allows modelling of the transport of orally administered radiopharmaceuticals, which previously were modelled to start in the stomach. The effective dose was calculated for 34 orally administered radiopharmaceuticals.

Paper II: IDACSTAR: a MCNP application to perform realistic dose estimations from internal or external contamination of radiopharmaceuticals

In Paper II, a Monte Carlo based stand-alone program was created called IDACSTAR. The main purpose of the program is to create Monte Carlo simulation input files for MCNP to facilitate absorbed dose and effective dose estimations from customisable SAF values and arbitrary source regions. The program also allows easy estimation of effective dose from skin contaminations. IDACSTAR is a graphical user interface where the user defines the activity in the voxel phantoms. For three predefined radionuclides, $^{18}$F, $^{99m}$Tc and $^{131}$I, the program performs automatic simulations of absorbed doses to organs and tissues and calculates the effective dose. The program has been applied on a hypothetical skin contamination case with $^{99m}$Tc, and on a real clinical extravasation case of a patient examined with $^{18}$F-FDG.

Paper III: Improved estimates of the radiation absorbed dose to the urinary bladder wall

In Paper III, sex-specific monoenergetic photon and electron dynamic SAF values are simulated ranging for the source region urinary bladder contents to the target regions bladder wall and contents with simulated urinary bladder contents ranging from 10 mL up to 800 mL. The resulting SAF values are based on a spherical bladder model and the anatomical and physiological data is based on the ICRP Publication 89. The generated SAF values are used to calculate the absorbed dose to the urinary bladder wall for two
radiopharmaceuticals: $^{18}$F-FDG and $^{99m}$Tc DTPA. The results show that using SAF values for a dynamic urinary volume, rather than fixed, will lead to a higher absorbed dose to the urinary bladder wall due to the smaller dynamic bladder volume compared to the fixed model. The smaller volume causes less attenuation in the bladder contents itself and thus higher SAF values and a higher absorbed dose to the urinary bladder wall.

**Paper IV: Organ doses and effective dose for five PET radiopharmaceuticals**

In **Paper IV**, the absorbed doses and effective doses are calculated for five radiopharmaceuticals intended for PET-examinations, using the computer program IDAC2.0 presented in **Paper I**. Diagnostic PET-examinations are dominated by the use of $^{18}$F-FDG, but there are other relevant radiopharmaceuticals commercially available or under development. For five of these radiopharmaceuticals, $^{18}$F-fluoride, $^{18}$F-fluoroethyltyrosine ($^{18}$F-FET), $^{18}$F-deoxyfluorothymidine ($^{18}$F-FLT), $^{18}$F-fluorocholine ($^{18}$F-choline), and $^{11}$C-raclopride, the effective dose is calculated to estimate the potential risk of stochastic effects for a representative population. The biokinetic models were obtained from ICRP Publication 128 and tissue weighting factors were taken from ICRP Publication 103. The estimated effective dose in mSv MBq$^{-1}$ was 0.015 for $^{18}$F-FET, 0.015 for $^{18}$F-FLT, 0.020 for $^{18}$F-choline, 0.0090 for $^{18}$F-fluoride, and 0.0044 for $^{11}$C-raclopride. For specific organ absorbed doses there are in some cases substantial differences to earlier estimation, but the effective dose was significantly different only for $^{18}$F-fluoride, for which a dose reduction of 48% was calculated using the IDAC2.0.

**Paper V: Dose management in conventional nuclear medicine imaging and PET**

**Paper V** is a review of the basic concepts of dose management in PET and conventional nuclear medicine imaging. The amount of activity administered in a nuclear medicine investigation determines the image quality and to a certain degree the diagnostic accuracy, but there are only a few studies trying to find an optimum activity. The paper states that nuclear medicine is far behind on image acceptable quality criteria and visual grading analysis compared to e.g. diagnostic radiology. The establishment of diagnostic reference levels is used as a method towards more optimal investigations in nuclear medicine. The main contribution of **Paper V** is the recommendation to adjust the administered activity by the patient’s weight. One of the keys to a successful dose management is continuous education and training of all staff categories involved in patient examinations.

**Paper VI: A biokinetic model and absorbed doses for systemic indium**

In **Paper VI**, a proposed systemic model of indium is presented. The model is based on both human and animal data, published between 1960 and 2016, for ionic indium, indium chloride, and indium arsenic which all has a strong binding to transferrin. The model consists of five different pools defined by 10 specific compartments and 21 specified transfer rates. The indium bound to transferrin is assumed to have a biological half-time of 10.5 hours. Absorbed doses and effective doses are calculated for $^{111}$In and $^{113m}$In. Revised effective dose calculations are also performed on the two previous indium models presented by the ICRP. Although the presented model still lacks sufficient reliable human data to
completely describe the distribution of indium in humans, it is likely a more correct biokinetic model in comparison to the published ICRP indium models which are both based on animal data only.
Chapter 5
Discussion and future outlook

The aim of this thesis was to improve radiation dose estimations for nuclear medicine examinations of patients. The improvement has been achieved by implementation of the new ICRP anatomical and voxelised mathematical models for adults, awaiting the models for paediatric patients. Concerning the necessary and equally important biokinetic models there is still much to do (Mattsson, 2015). Biokinetic modelling needs repeated quantitative measurements on patients/volunteers using the most advanced imaging equipment. The current trend is unfortunately the opposite, as exemplified by the dosimetry for amyloid binding radiopharmaceuticals (Scheinin, et al., 2007; O’Keefe et al., 2009; Koole et al., 2009; Lin et al., 2010; Pontecorvo et al., 2014). For these radiopharmaceuticals the biokinetic models are based on fewer subjects and time points than what has been common practice for earlier developed substances. The explanation might be that biokinetic studies are time consuming and requires several additional measurements on already heavily booked clinical imaging equipment. Today’s economy-driven health care leaves less and less room for this kind of clinical research. Important future projects would be to collect biokinetic information from a sufficient number of subjects for a specific radiopharmaceutical so that sex- and age-specific biokinetic model can be developed. It is highly desirable to get enough data to be able to construct biokinetic compartment models which describe the radionuclide transfer between various organs and circulating blood. In the specific absorbed fractions for the ICRP reference phantoms (ICRP, 2016) there is a specific source region defined for the circulating blood, hopefully allowing more biokinetic models to include a blood compartment in the future.

The small risk to later in life develop a radiation-induced cancer from a diagnostic radiopharmaceutical is currently estimated using the quantity effective dose. The radiation weighting factors used to estimate the effective dose is set to 1 for photons and electrons from radionuclides in diagnostic nuclear medicine. However, for very low energy electrons like those from Auger electron emitters (like $^{51}$Cr, $^{67}$Ga, $^{99m}$Tc, $^{111}$In, and others) and bound to DNA, ICRP acknowledges that a larger radiation weighting factor may be appropriate, even if no specific value is recommended. Humm et al. (1994) recognised that DNA-incorporated radionuclides emitting Auger electrons have a similar effect as $\alpha$-particles and recommends a radiation weighting factor of 20 for stochastic effects and 10 for deterministic effects. These factors are hence given for subcellular distributions, which if taken into account e.g. by compartmental modelling of the intracellular radionuclide distribution, may have an impact on the effective dose. The subcellular distribution and microdosimetry could be of high importance for risk estimations.
There is also a need to improve the estimation of stochastic effects for various population groups. One reason for this is the sex, age, and population unspecific nature of the effective dose protection unit (ICRP, 2007). It is questionable how well the data of the Life Span Study applies to the exposure situations in diagnostic nuclear medicine. The current risk estimates assume a linear no-threshold dose/risk model and a dose and dose rate effectiveness factor. Epidemiological studies based on dose data generated today and during the next decades are needed to improve risk estimations for stochastic effects.

An interesting future possibility is complete and automated segmentation of organs and structures in the CT- or MR-images from each individual patient. This will facilitate individual absorbed dose estimations and might, combined with a dose tracking system, generate sufficient epidemiological data for more accurate predictions of stochastic effects. In addition, specific subgroups based on physiological parameters may be identified, and form the basis for more specific biokinetic models. On the other hand, future development of tracers based on radionuclides with short physical half-lives, i.e. from seconds or up to a few minutes, would make individual differences minimal and general biokinetic models would likely be sufficient.

In the coming years the ICRP will also publish ten paediatric mathematical anatomical models together with mathematical models of an adult pregnant female and her developing embryo/foetus at different stages during her pregnancy. The implementation of these mathematical models into nuclear medicine will be much less time consuming using the framework presented in this thesis.
Chapter 6
Conclusions

The work underlying this thesis has led to the following conclusions:

- Absorbed dose calculations for a specific radiopharmaceutical in diagnostic nuclear medicine can be automated for more detailed mathematically voxelised reference models.

- Revision of descriptive models to systemic biokinetic models will provide more realistic biokinetic models.

- Effective dose estimations dedicated for diagnostic nuclear medicine based on the definitions in ICRP Publication 103 can be performed with the new anatomical mathematical models and the modified biokinetic models using the software developed in this thesis.

- Voxelised mathematical models creates possibilities to develop new methods to calculate the absorbed dose and facilitates dose estimation in subregions such as part of the skin, kidneys, or brain.

- A dynamic urinary bladder model provides more degrees of freedom and likely results in more realistic absorbed dose estimation than the reference mathematical models, which assume a fixed volume of the urinary bladder.
Bibliography

Andersson, M., Johansson, L., Minarik, D., Mattsson, S., Leide-Svegborn, S. An upgrade of the internal dosimetry computer program IDAC. In: Medical Physics in the Baltic States 10. (Ed. by D. Adlenè), Kaunas University of Technology 2012 120-123.


Cristy, M., Eckerman, K. Specific absorbed fractions of energy at various ages from internal photons sources. ORNL/TM-8381 V1-V7. Oak Ridge National Laboratory 1987.


ICRU. Fundamental quantities and units for ionizing radiation(revised) ICRU report no.85 Journal of the ICRU 11. 2011..


Internal dosimetry of radiopharmaceuticals in diagnostic nuclear medicine is based on biokinetic and anatomical models. The biokinetic model describes the uptake and retention of the radionuclide through the human body and where the nuclide decays. The anatomical models are mathematical models and are used to estimate the energy absorbed in the body from each decay. This means that the regions defining the biokinetic models also have to be defined in the mathematical anatomic models. A new biokinetic model is created and older models are modified to fit the new adult anatomic models presented by the ICRP and ICRU. New tools are developed to facilitate the use of the new voxel based anatomic models to perform revised absorbed dose and effective dose estimations. This book is the doctoral thesis of Martin Andersson and discusses the implementation of new voxel based mathematical models into diagnostic nuclear medicine. When not working with internal dosimetry Martin likes long walks by the beach and fine dining.